ALKS News and Press, Alkermes plc From 05/28/24

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 PR Newswire – Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations &#x...

2024-05-25 12:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised...

2024-05-23 13:30:04 ET Piper Sandler analyst issues BUY recommendation for ALKS on May 23, 2024 12:00PM ET. The previous analyst recommendation was Buy. ALKS was trading at $24.085 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...

2024-05-22 09:30:09 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for ALKS on May 22, 2024 07:26AM ET. The previous analyst recommendation was Overweight. ALKS was trading at $24.34 at issue of the analyst recommendation. The overall analyst consensus : B...

2024-05-17 08:27:04 ET Summary Alkermes is positioned for outperformance in the pharmaceutical sector due to its conservative cash-heavy balance sheet and high-margin business model. The company focuses on therapies for alcohol dependence, opioid dependence, schizophrenia, bipolar...

2024-05-15 14:20:39 ET Summary This monthly article series shows aggregate industry metrics in the healthcare sector. All healthcare subsectors are overvalued based on my metrics. Pharmaceuticals/biotechnology has the lowest scores in both value and quality. Invesco S&P 50...

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences PR Newswire ̶  Results from Long-Term Safety Study and Data from Healthcare Resource Utilization Research Offer Insights into Treatment Experiences for ...

2024-05-02 07:10:00 ET Summary Q1 earnings growth expectations have sharply declined more than usual as we enter earnings season. Over the past three months, Q1 growth projections have been adjusted downward by 21.5 percentage points, settling at a current year-over-year decline o...

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk PR Newswire DUBLIN , May 2, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Irela...

2024-05-01 11:20:07 ET Alkermes plc (ALKS) Q1 2024 Earnings Conference Call May 01, 2024 08:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Blair Jackson - Chief Operating Officer Todd Nichols - Chief ...